What did @nursey_mercy actually say?
The claim is that PT-141 is "almost instant" in how it works, that it produces "stimulation or arousal" and a "heightened sense of things," and that it can be taken by injection or nasal spray. The creator also throws in that bodybuilders used it "to get an extra pump" because of a mind-body connection effect.
To be fair, the video is not claiming PT-141 cures a disease or quoting fabricated statistics. But phrases like "almost instant" and the bodybuilder pump anecdote slide into exaggeration territory, and the whole framing leans on social proof from a client base rather than any clinical grounding. The creator is essentially saying: trust me, my Austin clients love it. That is not nothing, but it is also not evidence.
Does the science back this up?
Partially, yes. PT-141 (bremelanotide) has real clinical data behind it. The FDA approved it in 2019 under the brand name Vyleesi specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through melanocortin receptors in the brain, not through vascular pathways like PDE5 inhibitors, which makes it genuinely distinct from other options.
Clayton et al. (2016, Journal of Sexual Medicine) and the phase 3 RECONNECT trials showed statistically significant increases in satisfying sexual events and reduced distress in women with HSDD. So the core premise, that PT-141 can address low libido in women, has real support. The nasal spray delivery route also has clinical precedent. However, the word "instant" is doing a lot of heavy lifting here. Clinical studies show onset typically within 45 minutes to 1.5 hours, which is not the same thing as instant.
What did they get wrong (or right)?
The bodybuilder claim is where things go sideways. Saying bodybuilders used PT-141 "to get an extra pump" conflates two very different things. The mechanism is central nervous system melanocortin receptor activation, specifically MC3R and MC4R. There is no peer-reviewed evidence that this translates to enhanced muscular pump or performance. This appears to be gym-culture mythology attached to a legitimate peptide, and it muddies the actual science.
The "almost instant" framing is also misleading. The FDA label for Vyleesi specifies administration 45 minutes before anticipated sexual activity. That is a scheduled window, not an on-demand switch. Palatin Technologies' own trial data confirms the delayed onset. Calling it instant could lead someone to mistime use or misunderstand what the compound actually does.
What the creator got right: PT-141 does work via a mechanism distinct from hormonal therapies, the dual-route delivery (injection and nasal spray) is accurate, and low libido in perimenopausal or postmenopausal women is a real, underaddressed clinical issue that deserves more conversation.
What should you actually know?
PT-141 has a side effect profile worth knowing before you get excited about it. Nausea is the most common adverse event, reported in roughly 40% of participants in the RECONNECT trials (Simon et al., 2019, Obstetrics and Gynecology). Flushing and transient hypertension were also documented. The FDA label includes a contraindication for use with high-risk cardiovascular conditions. None of this appears in the video.
Compounded PT-141 is widely available through telehealth platforms, but it is not equivalent to FDA-approved Vyleesi in terms of regulatory oversight, and the purity and dosing of compounded versions can vary. Anyone considering this should have a real clinical consultation, not a TikTok recommendation. Low libido in women can have hormonal, relational, psychological, and medication-related causes, and treating it responsibly means evaluating those factors first.
- PT-141 is FDA-approved for HSDD in premenopausal women as bremelanotide (Vyleesi)
- Onset is 45 to 90 minutes, not instant
- Nausea affects a significant percentage of users based on trial data
- The bodybuilder pump claim has no clinical support
- Compounded PT-141 requires a legitimate prescription and clinical evaluation